Reduced granulocytosis in PLSCR^−/− mice treated with G-CSF.

Human recombinant G-CSF was injected subcutaneously into 5 each age-matched WT (■) and PLSCR1^−/− (□) male mice at doses of 120 μg/kg at time 0 and daily thereafter. Blood samples were collected before and 18, 66, and 114 hours after the initial G-CSF injection. Neutrophil counts were derived from whole blood WBC counts and WBC differential counts. **P < .01 compared with WT.